cebranopadol   Click here for help

GtoPdb Ligand ID: 8866

Synonyms: GRT 6005 | GRT-6005 | GRT6005
Compound class: Synthetic organic
Comment: This compound is a novel benzenoid opioid analgesic [2-3,5], being assessed in clinical trials for various acute and chronic pain conditions. The compound is non-selective, acting at more than one member of the opioid receptor family [1,4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 28.26
Molecular weight 378.21
XLogP 4.5
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Fc1ccc2c(c1)c1CCOC3(c1[nH]2)CCC(CC3)(N(C)C)c1ccccc1
Isomeric SMILES Fc1ccc2c(c1)c1CCOC3(c1[nH]2)CCC(CC3)(N(C)C)c1ccccc1
InChI InChI=1S/C24H27FN2O/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26H,10-15H2,1-2H3
No information available.
Summary of Clinical Use Click here for help
Cebranopadol advanced to Phase 3 clinical trial in patients with cancer-associated pain. However, Phase 3 study NCT01964378 was terminated due to an unworkable patient accrual rate. Phase 2 studies in other types of pain have been completed (click here to link to's list of cebranopadol (GRT6005) trials).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01964378 CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer Phase 3 Interventional Grünenthal GmbH